# Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

> **NCT01724866** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 148 (actual)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** SPI-2012
- **DRUG:** Pegfilgrastim
- **DRUG:** Docetaxel
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01724866
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-25
- **Primary completion:** 2014-08-12
- **Final completion:** 2014-08-12
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724866, "Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01724866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*